DC
AVNS

Davenport & Co’s Avanos Medical AVNS Stock Holding History

Davenport & Co’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,841
Closed -$237K – 590
2015
Q2 		$237K Sell
5,841
-160
-3% -$7.18K ﹤0.01% 504
2015
Q1 		$295K Buy
6,001
+224
+4% +$10.4K ﹤0.01% 485
2014
Q4 		$263K Buy
+5,777
New +$227K ﹤0.01% 490

Other funds holding AVNS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Shapiro Capital Management Atlanta, Georgia $1.6B AUM 13.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Davenport & Co's AVNS Position: Q3 2015 in Review

Davenport & Co sold out of Avanos Medical (AVNS) in Q3 2015, closing a stake of 5,841 shares — an estimated $237K sold.

Davenport & Co first reported a position in AVNS in Q4 2014 and held it in 3 quarters. The position peaked at $295K in Q1 2015. 353 funds tracked by Wall St. Rank hold AVNS as of Q3 2015.

  • Davenport & Co reported no remaining Avanos Medical position as of Q3 2015 after selling out during the quarter.
  • Davenport & Co sold 5,841 Avanos Medical shares in Q3 2015, an estimated $237K.
  • Davenport & Co first reported a position in Avanos Medical in Q4 2014 and held it in 3 quarters.
  • Davenport & Co's Avanos Medical position peaked at $295K in Q1 2015.
  • 353 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2015.

Based on Davenport & Co's 13F filing for Q3 2015, filed 23 Oct 2015.